Synthesis and In Vitro Evaluation of Polyethylene Glycol-Paclitaxel Conjugates for Lung Cancer Therapy

Pharmaceutical Research

Volumn 33, Issue 7, 2016, Pages 1671-1681

  Luo, Tian ^a,b   Magnusson, Johannes ^b   Préat, Véronique ^a   Frédérick, Raphael ^a   Alexander, Cameron ^b   Bosquillon, Cynthia ^b   Vanbever, Rita ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

drug conjugate; lung cancer; paclitaxel; polyethylene glycol; pulmonary drug delivery

Indexed keywords

MACROGOL; PACLITAXEL; PHOSPHATE BUFFERED SALINE; DELAYED RELEASE FORMULATION; DRUG CARRIER; MACROGOL DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CLICK CHEMISTRY; CONTROLLED STUDY; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG HALF LIFE; DRUG SCREENING; DRUG SOLUBILITY; DRUG STABILITY; DRUG SYNTHESIS; FEMALE; IN VITRO STUDY; LUNG CANCER; LUNG CANCER CELL LINE; LUNG LAVAGE; MELANOMA CELL; MELANOMA CELL LINE; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PH; PRIORITY JOURNAL; SUSTAINED DRUG RELEASE; ANIMAL; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG DELIVERY SYSTEM; HALF LIFE TIME; LUNG NEOPLASMS; MEDICINAL CHEMISTRY; MELANOMA, EXPERIMENTAL; PHARMACOLOGY; PROCEDURES; TUMOR CELL LINE;

ANIMALS; BRONCHOALVEOLAR LAVAGE; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FEMALE; HALF-LIFE; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; MOLECULAR WEIGHT; PACLITAXEL; POLYETHYLENE GLYCOLS;

EID: 84961206849     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-016-1908-2     Document Type: Article

References (40)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.
2. Patton JS, Fishburn CS, Weers JG. The lungs as a portal of entry for systemic drug delivery. Proc Am Phorac Soc. 2004;1:338–44.
3. Zarogoulidis P, Giraleli C, Karamanos NK. Inhaled chemotherapy in lung cancer: safety concerns of nanocomplexes delivered. Ther Deliv. 2012;3:1021–3.
4. Loira-Pastoriza C, Todoroff J, Vanbever R. Delivery strategies for sustained drug release in the lungs. Adv Drug Deliv Rev. 2014;75:81–91.
5. Roa WH, Azarmi S, Al-Hallak MH, Finlay WH, Magliocco AM, Lobenberg R. Inhalable nanoparticles, a non-invasive approach to treat lung cancer in a mouse model. J Control Release. 2011;150:49–55.
6. Garbuzenko OB, Saad M, Betigeri S, Zhang M, Vetcher AA, Soldatenkov VA, et al. Intratracheal versus intravenous liposomal delivery of siRNA, antisense oligonucleotides and anticancer drug. Pharm Res. 2009;26:382–94.
7. Waiteand CL, Roth CM. Nanoscale drug delivery systems for enhanced drug penetration into solid tumors: current progress and opportunities. Crit Rev Biomed Eng. 2012;40:21–41.
8. Jain RK. Transport of molecules in the tumor interstitium: a review. Cancer Res. 1987;47:3039–51.
9. Gursahani H, Riggs-Sauthier J, Pfeiffer J, Lechuga-Ballesteros D, Fishburn CS. Absorption of polyethylene glycol (PEG) polymers: the effect of PEG size on permeability. J Pharm Sci. 2009;98:2847–56.
10. Koussoroplis SJ, Paulissen G, Tyteca D, Goldansaz H, Todoroff J, Barilly C, et al. PEGylation of antibody fragments greatly increases their local residence time following delivery to the respiratory tract. J Control Release. 2014;187:91–100.
11. Bayard FJ, Thielemans W, Pritchard DI, Paine SW, Young SS, Backman P, et al. Polyethylene glycol-drug ester conjugates for prolonged retention of small inhaled drugs in the lung. J Control Release. 2013;171:234–40.
12. Duncan R, Vicent MJ, Greco F, Nicholson RI. Polymer-drug conjugates: towards a novel approach for the treatment of endrocine-related cancer. Endocr Relat Cancer. 2005;12 Suppl 1:S189–199.
13. Vicent MJ. Polymer-drug conjugates as modulators of cellular apoptosis. AAPS J. 2007;9:E200–207.
14. Krishnaand R, Mayer LD, Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci. 2000;11:265–83.
15. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science. 1992;258:1650–4.
16. Danhier F, Danhier P, De Saedeleer CJ, Fruytier AC, Schleich N, Rieux A, et al. Paclitaxel-loaded micelles enhance transvascular permeability and retention of nanomedicines in tumors. Int J Pharm. 2015;479:399–407.
17. Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res. 1996;56:2112–5.
18. Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer. 2001;37:1590–8.
19. Kiss L, Walter FR, Bocsik A, Veszelka S, Ozsvari B, Puskas LG, et al. Kinetic analysis of the toxicity of pharmaceutical excipients Cremophor EL and RH40 on endothelial and epithelial cells. J Pharm Sci. 2013;102:1173–81.
20. Chen S, Li L, Zhao C, Zheng J. Surface hydration: principles and applications toward low-fouling/nonfouling biomaterials. Polymer. 2010;51:5283–93.
21. Brancaand C, Magazu S. Hydration study of PEG/water mixtures by quasi elastic light scattering, acoustic and rheological measurements. J Phys Chem B. 2002;106:10272–6.
22. Navath RS, Wang B, Kannan S, Romero R, Kannan RM. Stimuli-responsive star poly(ethylene glycol) drug conjugates for improved intracellular delivery of the drug in neuroinflammation. J Control Release. 2010;142:447–56.
23. Li C, Price JE, Milas L, Hunter NR, Ke S, Yu DF, et al. Antitumor activity of poly(L-glutamic acid)-paclitaxel on syngeneic and xenografted tumors. Clin Cancer Res. 1999;5:891–7.
24. Zou Y, Fu H, Ghosh S, Farquhar D, Klostergaard J. Antitumor activity of hydrophilic Paclitaxel copolymer prodrug using locoregional delivery in human orthotopic non-small cell lung cancer xenograft models. Clin Cancer Res. 2004;10:7382–91.
25. Greenwald RB. PEG drugs: an overview. J Control Release. 2001;74:159–71.
26. Greenwald RB, Choe YH, McGuire J, Conover CD. Effective drug delivery by PEGylated drug conjugates. Adv Drug Deliv Rev. 2003;55:217–50.
27. Greenwald RB, Gilbert CW, Pendri A, Conover CD, Xia J, Martinez A. Drug delivery systems: water soluble taxol 2′-poly(ethylene glycol) ester prodrugs-design and in vivo effectiveness. J Med Chem. 1996;39:424–31.
28. Khandare JJ, Jayant S, Singh A, Chandna P, Wang Y, Vorsa N, et al. Dendrimer versus linear conjugate: influence of polymeric architecture on the delivery and anticancer effect of paclitaxel. Bioconjug Chem. 2006;17:1464–72.
29. Arpicco S, Stella B, Schiavon O, Milla P, Zonari D, Cattel L. Preparation and characterization of novel poly(ethylene glycol) paclitaxel derivatives. Int J Pharm. 2013;454:653–9.
30. Pilkington-Miksa M, Arosio D, Battistini L, Belvisi L, De Matteo M, Vasile F, et al. Design, synthesis, and biological evaluation of novel cRGD-paclitaxel conjugates for integrin-assisted drug delivery. Bioconjug Chem. 2012;23:1610–22.
31. Greenwald RB, Pendri A, Bolikal D. Highly water soluble taxol derivatives: 7-polyethylene glycol carbamates and carbonates. J Org Chem. 1995;60:331–6.
32. Deutsch HM, Glinski JA, Hernandez M, Haugwitz RD, Narayanan VL, Suffness M, et al. Synthesis of congeners and prodrugs. 3. Water-soluble prodrugs of taxol with potent antitumor activity. J Med Chem. 1989;32:788–92.
33. de Groot FM, van Berkom LW, Scheeren HW. Synthesis and biological evaluation of 2′-carbamate-linked and 2′-carbonate-linked prodrugs of paclitaxel: selective activation by the tumor-associated protease plasmin. J Med Chem. 2000;43:3093–102.
34. Lee J, Lee SC, Acharya G, Chang CJ, Park K. Hydrotropic solubilization of paclitaxel: analysis of chemical structures for hydrotropic property. Pharm Res. 2003;20:1022–30.
35. Ng AW, Bidani A, Heming TA. Innate host defense of the lung: effects of lung-lining fluid pH. Lung. 2004;182:297–317.
36. Rocks N, Bekaert S, Coia I, Paulissen G, Gueders M, Evrard B, et al. Curcumin–cyclodextrin complexes potentiate gemcitabine effects in an orthotopic mouse model of lung cancer. Br J Cancer. 2012;107:1083–92.
37. Sorrentino R, Morello S, Luciano A, Crother TR, Maiolino P, Bonavita E, et al. Plasmacytoid dendritic cells alter the antitumor activity of CpG-oligodeoxynucleotides in a mouse model of lung carcinoma. J Immunol. 2010;185:4641–50.
38. Yoshiura K, Nishishita T, Nakaoka T, Yamashita N, Yamashita N. Inhibition of B16 melanoma growth and metastasis in C57BL mice by vaccination with a syngeneic endothelial cell line. J Exp Clin Cancer Res. 2009;28:13.
39. Li W, Zhang P, De Clercq E, Lou H, Liu X. Current drug research on PEGylation with small molecular agents. Prog Polym Sci. 2013;38:421–44.
40. Hovorka O, St’astny M, Etrych T, Subr V, Strohalm J, Ulbrich K, et al. Differences in the intracellular fate of free and polymer-bound doxorubicin. J Control Release. 2002;80:101–17.